CRIS Current Research Information System

STEFANINI, BERNARDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.189
NA - Nord America 1.077
EU - Europa 885
SA - Sud America 169
AF - Africa 107
OC - Oceania 2
Totale 5.429
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.026
VN - Vietnam 922
CN - Cina 868
SG - Singapore 753
IT - Italia 348
HK - Hong Kong 189
KR - Corea 161
BR - Brasile 115
NL - Olanda 103
DE - Germania 86
IN - India 74
FR - Francia 67
JP - Giappone 62
FI - Finlandia 60
GB - Regno Unito 34
ZA - Sudafrica 34
IE - Irlanda 32
RU - Federazione Russa 30
SE - Svezia 30
AT - Austria 24
SC - Seychelles 23
TH - Thailandia 22
CA - Canada 21
PH - Filippine 21
AR - Argentina 20
MX - Messico 20
BD - Bangladesh 19
TW - Taiwan 15
CH - Svizzera 13
PK - Pakistan 13
PL - Polonia 12
BG - Bulgaria 11
CI - Costa d'Avorio 11
ID - Indonesia 11
IQ - Iraq 11
TR - Turchia 11
MA - Marocco 9
CO - Colombia 8
EC - Ecuador 7
MY - Malesia 6
UA - Ucraina 6
CL - Cile 5
RO - Romania 5
TG - Togo 5
VE - Venezuela 5
AZ - Azerbaigian 4
BE - Belgio 4
DZ - Algeria 4
EG - Egitto 4
ES - Italia 4
NG - Nigeria 4
UZ - Uzbekistan 4
AL - Albania 3
AO - Angola 3
BO - Bolivia 3
IL - Israele 3
JM - Giamaica 3
KE - Kenya 3
LB - Libano 3
LT - Lituania 3
PY - Paraguay 3
SA - Arabia Saudita 3
AE - Emirati Arabi Uniti 2
BF - Burkina Faso 2
CZ - Repubblica Ceca 2
JO - Giordania 2
PE - Perù 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
BH - Bahrain 1
BN - Brunei Darussalam 1
BT - Bhutan 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GR - Grecia 1
HR - Croazia 1
IS - Islanda 1
KG - Kirghizistan 1
KN - Saint Kitts e Nevis 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LV - Lettonia 1
LY - Libia 1
MO - Macao, regione amministrativa speciale della Cina 1
MU - Mauritius 1
NC - Nuova Caledonia 1
NP - Nepal 1
OM - Oman 1
PA - Panama 1
PS - Palestinian Territory 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
TV - Tuvalu 1
UG - Uganda 1
UY - Uruguay 1
Totale 5.429
Salva come PNG Salva come JPEG
Città #
Singapore 499
Hefei 330
Hanoi 246
Ho Chi Minh City 244
Ashburn 205
San Jose 172
Hong Kong 164
Bologna 144
Seoul 143
Santa Clara 75
Beijing 58
Tokyo 52
Da Nang 49
Los Angeles 47
Dallas 42
Lauterbourg 42
Council Bluffs 41
Bengaluru 34
Johannesburg 33
Milan 33
Boardman 32
Dublin 32
Haiphong 29
Helsinki 29
Lappeenranta 29
Frankfurt am Main 28
New York 28
Rome 27
Amsterdam 25
Buffalo 21
Guangzhou 19
Nuremberg 17
Redondo Beach 17
São Paulo 16
Can Tho 15
Orem 14
Tongling 14
Vienna 14
Falkenstein 13
Chicago 12
Abidjan 11
Bern 11
Montreal 11
Ninh Bình 11
Sofia 11
Warsaw 11
Munich 10
Shanghai 10
Shenzhen 10
Stockholm 10
The Dalles 10
Biên Hòa 9
Florence 9
Lahore 9
Mexico City 9
Vĩnh Long 9
Brooklyn 8
Chandler 8
Ha Long 8
Hải Dương 8
Jakarta 8
Baghdad 7
Bangkok 7
Chennai 7
Thái Nguyên 7
Boston 6
Bắc Ninh 6
Denver 6
Quận Ba 6
Shenyang 6
St Petersburg 6
Vũng Tàu 6
Bucharest 5
Curitiba 5
Houston 5
Hưng Yên 5
Lomé 5
Nha Trang 5
Phú Thọ 5
Quận Một 5
Salt Lake City 5
Shijiazhuang 5
Toronto 5
Tân Tiến 5
Ankara 4
Atlanta 4
Baku 4
Bexley 4
Brussels 4
Bến Tre 4
Castel Maggiore 4
Chengdu 4
Chongqing 4
Dongguan 4
Düsseldorf 4
New Taipei City 4
Palermo 4
Paris 4
Phoenix 4
Qingdao 4
Totale 3.479
Salva come PNG Salva come JPEG
Nome #
Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma 221
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs 217
Direct oral anticoagulants for the treatment of splanchnic vein thrombosis: A state of art 201
Intermediate-stage hepatocellular carcinoma: refining substaging or shifting paradigm? 194
Combination makes strength: a narrative review of transarterial radioembolization plus immune checkpoint inhibitors for hepatocellular carcinoma 181
Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma 171
Repeated Previous Transarterial Treatments Negatively Affect Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib 169
Association between anatomic variations of extrahepatic and intrahepatic bile ducts: Do look up! 161
Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma 155
TKIs in combination with immunotherapy for hepatocellular carcinoma 154
Presence of Hepatocellular Carcinoma Does Not Affect Course and Response to Anticoagulation of Bland Portal Vein Thrombosis in Cirrhotic Patients 151
Very Low Alcohol Consumption Is Associated with Lower Prevalence of Cirrhosis and Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease 150
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma 146
Exploring occupational toxicant exposures in patients with metabolic dysfunction-associated steatotic liver disease: A prospective pilot study 140
Osteosarcopenia in NAFLD/MAFLD: An Underappreciated Clinical Problem in Chronic Liver Disease 137
Radiological Features of Microvascular Invasion of Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease 136
Outcome of hepatic resection for HCC in ideal and non-ideal candidates 134
Advancements in immunotherapy for hepatocellular carcinoma 117
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients 112
Comparative Analysis of Subclassification Systems in Patients with Intermediate-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Classification B) Receiving Systemic Therapy 111
Targeted therapies for gallbladder cancer: an overview of agents in preclinical and clinical development 102
A Case of Advanced Hepatocellular Carcinoma with Bone Metastases Managed with Tyrosine Kinase Inhibitors and Aggressive Palliative Radiation Therapy: Role of Combination Therapy for Extending Survival 95
Etiology of Hepatocellular Carcinoma May Influence the Pattern of Progression under Atezolizumab-Bevacizumab 94
RANK-RANKL-OPG Axis in MASLD: Current Evidence Linking Bone and Liver Diseases and Future Perspectives 93
Surveillance for hepatocellular carcinoma: current status and future perspectives for improvement 86
Contrast-enhanced ultrasound liver imaging reporting and data system: clinical validation in a prospective multinational study in North America and Europe 83
Letter to the editor on the article Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System in Diagnosing Hepatocellular Carcinoma: Diagnostic Performance and Interobserver Agreement by Zhou and collaborators 79
Liver Fat Quantification: When do We Need It? 75
Systemic inflammatory response markers improve the discrimination for prognostic model in hepatocellular carcinoma 73
Artificial intelligence in Ultrasound: Pearls and pitfalls in 2024 72
Perirenal ultrasound abnormality: When to think at Xantogranulomatous Erdheim-Chester disease 70
Ultrasound, the handyman serving our whole populations in the post COVID-19 pandemic 69
What can real-world data teach us about treating patients with unresectable hepatocellular carcinoma? 67
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab 66
Pure red cell aplasia due to Parvovirus B19 infection and atezolizumab: case report and literature review 63
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 61
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence 60
Thinking outside the box: unconventional artificial intelligence algorithms in the detection and management of liver cirrhosis 60
Hepatitis C Eradication Improves Oncologic and Clinical Outcomes in Patients Treated With Atezolizumab Plus Bevacizumab 58
Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study 58
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab 57
Does aspirin use influence hepatocellular carcinoma and cholangiocarcinoma prognosis? 52
HCC Is the Predominant Liver-Related Event in MASLD: 2-Step Non-Invasive Algorithms to Stratify Risk in Non-Cirrhotic Patients 52
Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab 50
Recurrence rate, features, and outcome after hepatocellular carcinoma curative resection or ablation according to the IMbrave050 criteria: a real-world study 49
Liver Decompensation in Patients With Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: A Real-life Study 49
Liver stiffness measurement by SuperSonic Imagine two-dimensional shear wave elastography to predict hepatocellular carcinoma in non-cirrhotic metabolic dysfunction-associated steatotic liver disease 47
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab 47
Conversion to liver transplantation following atezolizumab-bevacizumab for HCC: the Bologna experience 46
Prediction of cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenib 45
Tumour Burden Score as a Predictor of Extrahepatic Progression After Transarterial Chemoembolization for Hepatocellular Carcinoma: An Observational Multicenter Study 43
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours 43
Occupational toxicants in MASLD: Bias, complexity, and future directions 42
Ultrasound in clinical enviroments: Where are we standing? 41
Post-immunotherapy second-line strategies for hepatocellular carcinoma: State of the art and ongoing trials 39
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis 38
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study 37
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Italian women: is liver fibrosis independent from menopause? 36
OS-064 Integrating gut microbiota composition and machine learning to predict therapeutic response in hepatocellular carcinoma treated with Atezolizumab and Bevacizumab: exploratory analysis from the phase 3b AMETHISTA study 34
THU-402-YI Real-world practice using liver stiffness measurement through two-dimensional shear wave elastography (SuperSonic Imagine) as a predictive tool for hepatocellular carcinoma risk in noncirrhotic MASLD patients 32
THU-401 Liver stiffness and MACE development: an intricate relationship 30
Nivolumab plus ipilimumab: A promising first-line therapy for hepatocellular carcinoma 26
Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study 25
Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab 8
Totale 5.610
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.187
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.187
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202216 0 0 0 0 0 0 1 7 2 0 2 4
2022/2023130 2 9 5 4 6 8 5 10 36 3 20 22
2023/2024166 10 14 12 11 12 30 7 28 10 12 12 8
2024/20251.104 24 78 76 73 102 46 103 32 47 106 122 295
2025/20264.194 375 444 284 375 434 167 605 274 922 314 0 0
Totale 5.610